BridgeMD
Tests treatment safety and results for Angina Pectoris
Official title Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries
ClinicalTrials.gov ID: NCT06424834
What this study is testing
What is Amlodipine?
Amlodipine is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for angina pectoris.
Also referred to as Norvasc, Katerzia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing. Participants will be treated with either medications that target the underlying cause of their chest pain or placebo for 4 weeks after a drug titration phase of 1-3 weeks.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- All patients with stable angina referred to the Stanford University Hospital cardiac catheterization laboratory for clinically indicated coronary...
- Absence of significant epicardial coronary artery disease on angiography
- Fractional flow reserve \> 0.80 And ≥ 1 of the following:
- Epicardial coronary spasm on acetylcholine testing
- Microvascular spasm on acetylcholine testing
You likely can't join if
- Acute coronary syndrome less than one week prior to enrolment
- Cardiomyopathy
- Contraindications to beta-blockers or calcium channel blockers
- Baseline systolic blood pressure \< 95 mmHg
- Baseline heart rate \< 55 bpm
See the full eligibility criteria
- All patients with stable angina referred to the Stanford University Hospital cardiac catheterization laboratory for clinically indicated coronary function testing are eligible for inclusion into the study. Specific for...
- Absence of significant epicardial coronary artery disease on angiography
- Fractional flow reserve \> 0.80 And ≥ 1 of the following:
- Epicardial coronary spasm on acetylcholine testing
- Microvascular spasm on acetylcholine testing
- Coronary flow reserve \< 2.5
- Index of microcirculatory resistance ≥ 25
- Myocardial bridge on intravascular ultrasound with dobutamine resting full-cycle ratio ≤ 0.76
- Acute coronary syndrome less than one week prior to enrolment
- Cardiomyopathy
- Contraindications to beta-blockers or calcium channel blockers
- Baseline systolic blood pressure \< 95 mmHg
- Baseline heart rate \< 55 bpm
The study team makes the final eligibility decision.
Where it's taking place
- Palo Alto, California, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Palo Alto, California, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.